Nutraceutical company TOSLA announced the launch of its ready-to-market Signaling Collagen Shot in partnership with Geltor, a pioneer in biotechnology. The liquid supplement is certified vegan and features Geltor’s PrimaColl, a biomimetic type 21 signaling collagen polypeptide.
According to the company’s press release, PrimaColl supports key skin-signaling pathways and improved appearance of skin. Further, the supplement is paired with TOSLA’s VELIOUS Flavor Technology, a patented technology to mask unwanted tastes of active ingredients.
“TOSLA was built on the belief that efficacy alone is not enough – ritual drives results,” said Uroš Gotar, chief innovation officer. “Our partnership with Geltor brings together breakthrough biotechnology and sensorial design in a way that feels seamless in daily life. With PrimaColl, we are transforming advanced science into an experience consumers can look forward to, because when wellness becomes a ritual, adherence follows, and results are realized over time.”
Geltor evaluated PrimaColl in a randomized, double-blind, placebo-controlled clinical study of 170 participants over 12 weeks. According to the results, 80-92% of participants showed improvements in skin firmness, elasticity, moisturization and wrinkle depth after consuming between one and 2.5 grams daily.
“Bio-designed ingredients like PrimaColl represent an evolution in collagen science, but innovation means nothing if it doesn’t reach consumers,” said Alex Lorestani, chief executive officer and co-founder of Geltor. “Our partnership with TOSLA bridges that gap, transforming breakthrough biotechnology into a ready-to-market solution that brands can confidently launch. This collaboration proves that when you unite ingredient innovation with formulation expertise, you create something consumers actually want to use every day.”
The Signaling Collagen Shot will debut at Vitafood in Barcelona, Spain, and at NYSCC Suppliers’ Day in New York City.
